| Company Name: |
Tianjin Kailiqi Biotechnology Co., Ltd.
|
| Tel: |
15076683720 |
| Email: |
klq@cw-bio.com |
| Products Intro: |
Product Name:UNC7467
CAS:2922283-43-8
Purity:大于98% Package:1g,5g,10g,25g根据客户需要分装 Remarks:Not For Human Use, Lab Use Only.
|
| Company Name: |
Changzhou Chenhong Biotechnology Co., Ltd.
|
| Tel: |
+86-0519-85788828 +86-13775037613 |
| Email: |
sales@chemrenpharm.com |
| Products Intro: |
Product Name:UNC7467
CAS:2922283-43-8
Purity:99% Package:50mg;100mg;250mg;500mg;1g;5g
|
2,1-Benzisoxazole-5-carboxylic acid, 3-[1,1′-biphenyl]-4-yl- manufacturers
- UNC7467
-
- $30.00 / 1mg
-
2025-11-10
- CAS:2922283-43-8
- Min. Order:
- Purity: 98.28%
- Supply Ability: 10g
|
| | 2,1-Benzisoxazole-5-carboxylic acid, 3-[1,1′-biphenyl]-4-yl- Basic information |
| | 2,1-Benzisoxazole-5-carboxylic acid, 3-[1,1′-biphenyl]-4-yl- Chemical Properties |
| Boiling point | 599.2±35.0 °C(Predicted) | | density | 1.299±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted) | | solubility | DMSO: Slightly soluble: 0.1-1 mg/ml | | form | Solid | | pka | 3.62±0.30(Predicted) | | color | Light yellow to yellow |
| | 2,1-Benzisoxazole-5-carboxylic acid, 3-[1,1′-biphenyl]-4-yl- Usage And Synthesis |
| Uses | UNC7467 is a potent IP6K inhibitor with values of 4.9, 8.9 and 1320 nM for IP6K2, IP6K1 and IP6K6, respectively. UNC7467 reduces levels of inositol pyrophosphates. UNC7467 can be used for obesity research[1]. | | in vivo | UNC7467 (5 mg/kg; i.p.; daily, for 4 weeks; diet-induced obesity mice) ameliorated diet induced obesity, insulin resistance, and hepatic steatosis[1].
UNC7467 (1-5 mg/kg; i.v. and i.p.; diet-induced obesity mice) exhibits low clearance (13.7 (mL/min)/kg) and large AUClast (6054 h?ng/mL for intra venous (i.v.) and 2527 h?ng/mL for intraperitoneal (i.p.)) in mice at 5 mg/kg dose[1]. | Animal Model: | Diet-induced obesity (DIO) mice[1] | | Dosage: | 5 mg/kg | | Administration: | Intraperitoneal injection; daily, for 4 weeks | | Result: | Improved glycemic profiles, ameliorated hepatic steatosis, and reduced weight gain without altering food intake. |
| Animal Model: | Diet-induced obesity (DIO) mice[1] | | Dosage: | 5 mg/kg (Pharmacokinetic Analysis) | | Administration: | Intravenous injection and intraperitoneal injection | | Result: | 1.19| route | iv | ip | | Dose (mg/kg) | 5 | 5 | | AUClast (h*ng/mL) | 6054 | 2527 | | CL (mL/min/kg) | 13.7 | |
|
| | References | [1] Zhou Y, et, al. Development of Novel IP6K Inhibitors for the Treatment of Obesity and Obesity-Induced Metabolic Dysfunctions. J Med Chem. 2022 May 12;65(9):6869-6887. DOI:10.1021/acs.jmedchem.2c00220 |
| | 2,1-Benzisoxazole-5-carboxylic acid, 3-[1,1′-biphenyl]-4-yl- Preparation Products And Raw materials |
|